Literature DB >> 29275977

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Alan J Thompson1, Brenda L Banwell2, Frederik Barkhof3, William M Carroll4, Timothy Coetzee5, Giancarlo Comi6, Jorge Correale7, Franz Fazekas8, Massimo Filippi9, Mark S Freedman10, Kazuo Fujihara11, Steven L Galetta12, Hans Peter Hartung13, Ludwig Kappos14, Fred D Lublin15, Ruth Ann Marrie16, Aaron E Miller15, David H Miller17, Xavier Montalban18, Ellen M Mowry19, Per Soelberg Sorensen20, Mar Tintoré21, Anthony L Traboulsee22, Maria Trojano23, Bernard M J Uitdehaag24, Sandra Vukusic25, Emmanuelle Waubant26, Brian G Weinshenker27, Stephen C Reingold28, Jeffrey A Cohen29.   

Abstract

The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation. The following changes were made: in patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of multiple sclerosis; symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome; and cortical lesions can be used to demonstrate dissemination in space. Research to further refine the criteria should focus on optic nerve involvement, validation in diverse populations, and incorporation of advanced imaging, neurophysiological, and body fluid markers.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29275977     DOI: 10.1016/S1474-4422(17)30470-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  1069 in total

Review 1.  [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].

Authors:  Orhan Aktas; Tania Kümpfel
Journal:  Nervenarzt       Date:  2021-03-16       Impact factor: 1.214

2.  Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity.

Authors:  Themis Alissafi; Lydia Kalafati; Maria Lazari; Anastasia Filia; Ismini Kloukina; Maria Manifava; Jong-Hyung Lim; Vasileia Ismini Alexaki; Nicholas T Ktistakis; Triantafyllos Doskas; George A Garinis; Triantafyllos Chavakis; Dimitrios T Boumpas; Panayotis Verginis
Journal:  Cell Metab       Date:  2020-07-31       Impact factor: 27.287

Review 3.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

4.  Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI.

Authors:  M Absinta; P Sati; A Fechner; M K Schindler; G Nair; D S Reich
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-03       Impact factor: 3.825

Review 5.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

6.  Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.

Authors:  Anne I Boullerne; Guy R Adami; Joel L Schwartz; Demetrios Skias; Mark Maienschein-Cline; Stefan J Green; Douglas L Feinstein
Journal:  J Neuroimmunol       Date:  2020-04-07       Impact factor: 3.478

Review 7.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

8.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

9.  Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis.

Authors:  Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini
Journal:  Sci Immunol       Date:  2020-11-20

10.  The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.

Authors:  Jan Kolcava; Monika Hulova; Lucie Rihova; Josef Bednarik; Pavel Stourac
Journal:  Neurol Sci       Date:  2020-11-17       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.